Merck KGaA, Darmstadt, Germany, announces completion of Sigma-Aldrich Acquisition

Article

Merck KGaA announces the completion of the acquisition of Sigma-Aldrich, a St. Louis-based life-sciences and technology company.

Merck KGaA, Darmstadt, Germany announced on Nov. 18, 2015, the completion of their acquisition of Sigma-Aldrich, a St. Louis-based life-science and technology company, according to a press release.

The $17-billion acquisition follows last week’s approval from the European Commission, the final antitrust condition required to close the Sigma-Aldrich transaction. 

The acquisition boosts Merck KGaA to around 50,000 employees in 67 countries worldwide.

In 2014, Merck KGaA’s life sciences division grossed a total of €4.6 billion (approximately $4.89 billion) in sales. With the addition of Sigma-Aldrich, the company expects a total gross of between €12.6 billion (approximately $13.4 billion) and €12.8 billion (approximately $13.61 billion) for 2015.

Merck KGaA announced the acquisition of Sigma-Aldrich in a September 2014 press release, saying this decision would allow them to increase their presence in the North American and Asian markets.

According to the company, the acquisition merged Merck KGaA’s existing life-sciences division, EMD Millipore, with Sigma-Aldrich, now MilliporeSigma.

Merck KGaA has made nearly €38 billion (approximately $40.4 billion) in acquisitions and divestments in the past 10 years, expanding their business in the areas of science, technology, healthcare, and life science. 

Source: Merck KGaA

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content